An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...

This year the biosimilars to Stelara (ustekinumab) stand to be the stars of the biosimilars show. The FDA has approved seven ...

Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® received MHRA approval for both subcutaneous and intravenous formulations, to ...

Regulatory ApprovalFormycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 15.01.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...

SEOUL, Jan. 23 (Korea Bizwire) — Celltrion Inc.’s autoimmune disease treatment, SteQeyma, has been launched in five major ...

On December 17, 2024, the Competition Tribunal (the Tribunal) issued reasons for its decision to dismiss an application for leave to bring a ...

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...

OtulfiTM received a Health Canada Notice of Compliance (NOC) approval on December 30th for both subcutaneous and intravenous formulationsWith this approval, Fresenius Kabi Canada's immunology ...

Celltrion's ustekinumab biosimilar is now available in France, Italy, Spain, Britain and Germany after securing European ...

In the pivotal trial, patients treated with Omvoh experienced significant improvements in clinical remission and endoscopic ...

With an increased confidence in the company’s prospects, HSBC raised its earnings estimates for Biocon, projecting ...